Phase 3 pivotal trial of ARV 110 in the patients with AR T878/H875 tumor mutations
Latest Information Update: 15 Nov 2022
At a glance
- Drugs Bavdegalutamide (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Arvinas
- 08 Nov 2022 According to a Arvinas media release, Confirm final dose selection and secure final health authority feedback on trial protocol is expected in 1H 2023.
- 04 Aug 2022 According to a Arvinas media release, the company plans to initiate a Phase 3 trial in metastatic castration-resistant prostate cancer, or mCRPC, for patients with AR T878/H875 tumor mutations in 2H 2023.
- 28 Feb 2022 According to a Arvinas media release, this trial is expected to begin by year end-2022.